Cargando…

A short course of oral ranitidine as a novel treatment for toddler’s diarrhea: a parallel-group randomized controlled trial

BACKGROUND: The current paradigm for treating toddler’s diarrhea comprises dietary modification and fluid restriction. Previous studies show that probiotics and proton-pump inhibitors (PPIs) or H(2) blockers could control diarrhea associated with functional gastrointestinal disorders (FGIDs). This s...

Descripción completa

Detalles Bibliográficos
Autores principales: Uwaezuoke, Samuel N., Ndu, Ikenna K., Eneh, Chizoma I., Anusiem, Chikere A., Ayuk, Adaeze C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422520/
https://www.ncbi.nlm.nih.gov/pubmed/32781992
http://dx.doi.org/10.1186/s12887-020-02267-7
_version_ 1783570020200087552
author Uwaezuoke, Samuel N.
Ndu, Ikenna K.
Eneh, Chizoma I.
Anusiem, Chikere A.
Ayuk, Adaeze C.
author_facet Uwaezuoke, Samuel N.
Ndu, Ikenna K.
Eneh, Chizoma I.
Anusiem, Chikere A.
Ayuk, Adaeze C.
author_sort Uwaezuoke, Samuel N.
collection PubMed
description BACKGROUND: The current paradigm for treating toddler’s diarrhea comprises dietary modification and fluid restriction. Previous studies show that probiotics and proton-pump inhibitors (PPIs) or H(2) blockers could control diarrhea associated with functional gastrointestinal disorders (FGIDs). This study aims to determine and compare the efficacy of a short course of oral ranitidine and a probiotic in the treatment of toddler’s diarrhea. METHODS: This study was a parallel-group randomized controlled trial (RCT). We sequentially enrolled 40 patients who met the eligibility criteria. We randomly assigned 20 patients to the oral ranitidine group, ten patients to the probiotic group, and ten patients to the placebo group. In the oral ranitidine group, patients received oral ranitidine (3 mg/kg/day) once daily for 10 days; in the probiotic and placebo groups, they were administered 5 to 10 billion colony-forming units (CFUs) per day of lyophilized Lactobacillus rhamnosus and 50 mg of once-daily oral vitamin C tablet respectively for 10 days. Stool frequency and consistency on the 10th day of the interventions were recorded as the primary outcomes. We used the Student’s t-test to determine if there were significant differences in the mean daily stool frequencies in the three intervention groups. A p-value < 0.05 was adopted as the level of statistical significance. RESULTS: In the ranitidine group, stool frequency decreased significantly from an average of five per day on the first day to an average of approximately one per day on the 10th day of intervention (t = 10.462, p <  0.001). Additionally, stool consistency normalized on the 10th day of intervention. In the probiotic group, there was a significant reduction in stool frequency from an average of five per day on the first day to four per day on the 10th day (t = 2.586, p = 0.041), although stool consistency remained loose. However, stool consistency and frequency were not significantly affected in the placebo group (t = 1.964, p = 0.072). CONCLUSION: Oral ranitidine is more effective than probiotics in reducing stool frequency and normalizing stool consistency in toddler’s diarrhea. We recommend multi-center trials with appropriate study designs to confirm and validate this finding. TRIAL REGISTRATION: ISRCTN, ISRCTN10783996. Registered 8 April 2016-Registered retrospectively.
format Online
Article
Text
id pubmed-7422520
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74225202020-08-21 A short course of oral ranitidine as a novel treatment for toddler’s diarrhea: a parallel-group randomized controlled trial Uwaezuoke, Samuel N. Ndu, Ikenna K. Eneh, Chizoma I. Anusiem, Chikere A. Ayuk, Adaeze C. BMC Pediatr Research Article BACKGROUND: The current paradigm for treating toddler’s diarrhea comprises dietary modification and fluid restriction. Previous studies show that probiotics and proton-pump inhibitors (PPIs) or H(2) blockers could control diarrhea associated with functional gastrointestinal disorders (FGIDs). This study aims to determine and compare the efficacy of a short course of oral ranitidine and a probiotic in the treatment of toddler’s diarrhea. METHODS: This study was a parallel-group randomized controlled trial (RCT). We sequentially enrolled 40 patients who met the eligibility criteria. We randomly assigned 20 patients to the oral ranitidine group, ten patients to the probiotic group, and ten patients to the placebo group. In the oral ranitidine group, patients received oral ranitidine (3 mg/kg/day) once daily for 10 days; in the probiotic and placebo groups, they were administered 5 to 10 billion colony-forming units (CFUs) per day of lyophilized Lactobacillus rhamnosus and 50 mg of once-daily oral vitamin C tablet respectively for 10 days. Stool frequency and consistency on the 10th day of the interventions were recorded as the primary outcomes. We used the Student’s t-test to determine if there were significant differences in the mean daily stool frequencies in the three intervention groups. A p-value < 0.05 was adopted as the level of statistical significance. RESULTS: In the ranitidine group, stool frequency decreased significantly from an average of five per day on the first day to an average of approximately one per day on the 10th day of intervention (t = 10.462, p <  0.001). Additionally, stool consistency normalized on the 10th day of intervention. In the probiotic group, there was a significant reduction in stool frequency from an average of five per day on the first day to four per day on the 10th day (t = 2.586, p = 0.041), although stool consistency remained loose. However, stool consistency and frequency were not significantly affected in the placebo group (t = 1.964, p = 0.072). CONCLUSION: Oral ranitidine is more effective than probiotics in reducing stool frequency and normalizing stool consistency in toddler’s diarrhea. We recommend multi-center trials with appropriate study designs to confirm and validate this finding. TRIAL REGISTRATION: ISRCTN, ISRCTN10783996. Registered 8 April 2016-Registered retrospectively. BioMed Central 2020-08-11 /pmc/articles/PMC7422520/ /pubmed/32781992 http://dx.doi.org/10.1186/s12887-020-02267-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Uwaezuoke, Samuel N.
Ndu, Ikenna K.
Eneh, Chizoma I.
Anusiem, Chikere A.
Ayuk, Adaeze C.
A short course of oral ranitidine as a novel treatment for toddler’s diarrhea: a parallel-group randomized controlled trial
title A short course of oral ranitidine as a novel treatment for toddler’s diarrhea: a parallel-group randomized controlled trial
title_full A short course of oral ranitidine as a novel treatment for toddler’s diarrhea: a parallel-group randomized controlled trial
title_fullStr A short course of oral ranitidine as a novel treatment for toddler’s diarrhea: a parallel-group randomized controlled trial
title_full_unstemmed A short course of oral ranitidine as a novel treatment for toddler’s diarrhea: a parallel-group randomized controlled trial
title_short A short course of oral ranitidine as a novel treatment for toddler’s diarrhea: a parallel-group randomized controlled trial
title_sort short course of oral ranitidine as a novel treatment for toddler’s diarrhea: a parallel-group randomized controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422520/
https://www.ncbi.nlm.nih.gov/pubmed/32781992
http://dx.doi.org/10.1186/s12887-020-02267-7
work_keys_str_mv AT uwaezuokesamueln ashortcourseoforalranitidineasanoveltreatmentfortoddlersdiarrheaaparallelgrouprandomizedcontrolledtrial
AT nduikennak ashortcourseoforalranitidineasanoveltreatmentfortoddlersdiarrheaaparallelgrouprandomizedcontrolledtrial
AT enehchizomai ashortcourseoforalranitidineasanoveltreatmentfortoddlersdiarrheaaparallelgrouprandomizedcontrolledtrial
AT anusiemchikerea ashortcourseoforalranitidineasanoveltreatmentfortoddlersdiarrheaaparallelgrouprandomizedcontrolledtrial
AT ayukadaezec ashortcourseoforalranitidineasanoveltreatmentfortoddlersdiarrheaaparallelgrouprandomizedcontrolledtrial
AT uwaezuokesamueln shortcourseoforalranitidineasanoveltreatmentfortoddlersdiarrheaaparallelgrouprandomizedcontrolledtrial
AT nduikennak shortcourseoforalranitidineasanoveltreatmentfortoddlersdiarrheaaparallelgrouprandomizedcontrolledtrial
AT enehchizomai shortcourseoforalranitidineasanoveltreatmentfortoddlersdiarrheaaparallelgrouprandomizedcontrolledtrial
AT anusiemchikerea shortcourseoforalranitidineasanoveltreatmentfortoddlersdiarrheaaparallelgrouprandomizedcontrolledtrial
AT ayukadaezec shortcourseoforalranitidineasanoveltreatmentfortoddlersdiarrheaaparallelgrouprandomizedcontrolledtrial